[
    [
        {
            "time": "",
            "original_text": "医药行业周报：逐步布局一季报高增长核心资产",
            "features": {
                "keywords": [
                    "医药行业",
                    "一季报",
                    "高增长",
                    "核心资产"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药行业周报：逐步布局一季报高增长核心资产",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "国盛证券---医药生物行业周报：全民免疫迫在眉睫，新冠疫苗的热点问题怎么看【行业研究】",
            "features": {
                "keywords": [
                    "医药生物",
                    "全民免疫",
                    "新冠疫苗",
                    "热点问题"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国盛证券---医药生物行业周报：全民免疫迫在眉睫，新冠疫苗的热点问题怎么看【行业研究】",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "高瓴资本概念股普遍下滑，健康元、凯莱英、健帆生物、良品铺子、广联达领跌",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "概念股",
                    "下滑",
                    "健康元",
                    "凯莱英",
                    "健帆生物",
                    "良品铺子",
                    "广联达"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "消费品",
                    "软件"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "高瓴资本概念股普遍下滑，健康元、凯莱英、健帆生物、良品铺子、广联达领跌",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]